• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

Mylan Inc.

NASDAQ:MYL

$21.63 $0.35 (1.64%)

REAL-TIME: Last trade at

Senate passes FDA funding bill, Reuters reports

Mylan Announces Settlement Agreement in Patent Infringement Litigation Relating to Sunovion's Brovana® Product

Mylan launches generic version of Bonviva tablets in Italy and UK

Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy

Merck and Mylan Look to Benefit From Plan to Speed up FDA Reviews

Mylan credit ratings upgraded by Moody's

Moody's Upgrades Mylan

Mylan launches generic version of Viramune tablets

Mylan Launches Generic Version of Viramune® Tablets

FTC, Senate probing blocking of generic drug companies, Washington Post says

Generic Versions of Plavix Get FDA Approval

Mylan Launches Generic Version of Plavix® Tablets

Critical Alerts For Apple, ConocoPhillips, Yahoo, US Airways, and Mylan Released By InvestorsObserver

Equity Research on Mylan Inc. and Watson Pharmaceuticals Inc. -- Increased Sales Driving Generic Drug Makers Higher

Mylan Specialty L.P. Commemorates 15th Annual Food Allergy Awareness Week

Mylan M&A ranking raised to a 2 from a 3 at Goldman

Mylan launches generic version of Pfizer's Lipitor in five European countries

Mylan Launches Generic Lipitor® in Five European Countries

Mylan Inc. is on track …

Mylan Lifts Earnings Outlook, Plans $500 Mln Share Buyback

Mylan raises FY12 EPS to $2.45-$2.55 from $2.30-$2.50, consensus $2.42

Mylan Increases 2012 Guidance Range to $2.45 to $2.55 in Adjusted Diluted EPS

Mylan weakness creates buying opportunity, says Argus

Watson Pharmaceuticals can still deliver potent returns, Barron's says

Goldman to host a conference

Watson Pharmaceuticals Is No Ordinary Generic

Warner Chilcott confirms decision in Doryx patent litigation

Mylan Launches First Generic Version of Doryx® 150 mg

Teva settles Nuvigil litigation with Mylan

Mylan Announces Settlement Agreement for its First-to-File Generic Version of Nuvigil®

Merck wins U.S. Zetia/Vytorin patent infringement lawsuit against Mylan

Mylan to Partner with United Nations and Clinton Health Access Initiative to Fight Diarrhea Fatalities in Children in India

Mylan to Partner with United Nations and Clinton Health Access Initiative to Fight Diarrhea Fatalities in Children in India

Analysts Get Hooked On Watson, Actavis Drugs Deal

Mylan, Inc. (MYL) Tops Q1 EPS by 1c

Mylan reaffirms FY12 EPS view $2.30-$2.50, consensus $2.42

Mylan reports Q1 adj EPS 52c, consensus 50c

Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter

Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva

Mylan, Pfizer announce settlement agreement with Teva

See More Articles...